Nadim Ahmed Sells 13,515 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) CEO Nadim Ahmed sold 13,515 shares of Cullinan Therapeutics stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $14.47, for a total value of $195,562.05. Following the transaction, the chief executive officer directly owned 390,803 shares in the company, valued at approximately $5,654,919.41. The trade was a 3.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Nadim Ahmed also recently made the following trade(s):

• On Friday, February 20th, Nadim Ahmed sold 16,381 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $13.62, for a total value of $223,109.22.
• On Tuesday, December 23rd, Nadim Ahmed sold 9,922 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $10.01, for a total value of $99,319.22.

Cullinan Therapeutics Price Performance

NASDAQ CGEM opened at $15.21 on Friday. The company has a fifty day moving average price of $11.61 and a 200-day moving average price of $9.35. The firm has a market cap of $898.61 million, a price-to-earnings ratio of -4.60 and a beta of -0.09. Cullinan Therapeutics, Inc. has a 1 year low of $5.68 and a 1 year high of $15.23.

Hedge Funds Weigh In On Cullinan Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Cullinan Therapeutics by 1.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 48,051 shares of the company’s stock valued at $497,000 after buying an additional 888 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Cullinan Therapeutics by 62.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,696 shares of the company’s stock valued at $28,000 after acquiring an additional 1,036 shares during the last quarter. Kennedy Capital Management LLC grew its holdings in shares of Cullinan Therapeutics by 2.7% in the fourth quarter. Kennedy Capital Management LLC now owns 47,266 shares of the company’s stock valued at $489,000 after purchasing an additional 1,255 shares during the period. CWM LLC grew its holdings in shares of Cullinan Therapeutics by 51.5% in the fourth quarter. CWM LLC now owns 3,876 shares of the company’s stock valued at $40,000 after purchasing an additional 1,318 shares during the period. Finally, Rafferty Asset Management LLC increased its position in Cullinan Therapeutics by 3.8% during the third quarter. Rafferty Asset Management LLC now owns 40,729 shares of the company’s stock worth $242,000 after purchasing an additional 1,503 shares during the last quarter. Hedge funds and other institutional investors own 86.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Wedbush increased their price target on Cullinan Therapeutics from $25.00 to $34.00 and gave the company an “outperform” rating in a research report on Tuesday, December 9th. BTIG Research raised their target price on Cullinan Therapeutics from $32.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, November 24th. Guggenheim started coverage on shares of Cullinan Therapeutics in a report on Monday, February 2nd. They issued a “buy” rating and a $30.00 price target on the stock. Wall Street Zen downgraded shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, February 8th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cullinan Therapeutics in a research note on Monday, December 29th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.33.

More Cullinan Therapeutics News

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: Near-zero reported short interest reduces potential forced selling and can limit downside pressure, supporting the stock’s move higher. Short Interest Report
• Positive Sentiment: Analyst coverage is tilted positive: several firms (Guggenheim, Citi, HC Wainwright) carry Buy ratings and materially higher price targets than the current quote, creating an upside narrative that can attract buyers. Analyst Coverage
• Positive Sentiment: Institutional investors increased positions in Q4 (Invesco, Virtus, Susquehanna and others reported larger stakes), which can provide buying support and signal conviction from larger market participants. Institutional Activity
• Neutral Sentiment: Market context: broader risk-on/risk-off swings (crypto weakness noted in recent headlines) can affect small-cap biotechs indiscriminately; this is a macro factor rather than company-specific news. Macro/Crypto Headline
• Neutral Sentiment: Some shops have trimmed ratings recently (a few downgrades), creating dispersion in expectations—this can increase volatility but does not decisively change the bullish analyst narrative. Analyst Notes
• Negative Sentiment: Multiple senior insiders sold sizable blocks on Feb. 24–25, including CEO Nadim Ahmed (13,515 shares) and other executives—clustered insider sales can be perceived as insider monetization and pressure sentiment. CEO Sale Filing
• Negative Sentiment: Director/executive Jennifer Michaelson executed multiple recent sales (Feb. 23–25 series of transactions), further trimming insider holdings and amplifying concerns about insider cash-outs. Insider Trades Summary

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.